Home exercise during neoadjuvant therapy for pancreatic cancer

MS-N176 · Exercise and rehabilitation · pancreatic-cancer patients receiving neoadjuvant therapy before intended surgery

Evidence at a glance

Question: Does a prescribed home aerobic-and-resistance program outperform enhanced activity advice during neoadjuvant pancreatic-cancer treatment?
Finding: Both groups improved walking capacity; the prescribed program did not significantly outperform enhanced usual care.
Evidence label: Negative randomized evidence for added benefit versus active control
Benefit: Strength-training frequency increased, but clinical and quality-of-life outcomes did not differ.
Certainty: Moderate for no added functional benefit in this pragmatic design.
Risk: Unsupervised exercise excluded people with unstable disease or severe pain; safety events were not quantified in the extracted results.
Cancer-control boundary: Exercise did not increase the pancreatectomy rate and did not test tumor response as a primary outcome.

What was studied

People with biopsy-confirmed pancreatic cancer receiving at least six weeks of chemotherapy and/or radiation before anticipated pancreatectomy.

Design and comparator: Pragmatic randomized trial; prescribed home aerobic and resistance exercise versus enhanced usual care with activity trackers, nutrition counseling and exercise information.
Participants: 151 eligible participants randomized; 125 completed the primary six-minute-walk assessment.
Intervention: Moderate aerobic exercise at least 30 minutes on five days weekly plus resistance training at least twice weekly, with bands and instruction, throughout a median 22–24-week neoadjuvant period.
Primary outcome and follow-up: Change in six-minute walk distance; a 14-meter improvement was considered clinically meaningful.

What the study found

Six-minute walk distance improved in both enhanced usual care (+18.6±56.8 m) and prescribed exercise (+27.3±68.1 m), without a significant between-group difference. Activity minutes were similar; strength sessions increased more with prescription. Quality of life, clinical outcomes and pancreatectomy rates (49% vs 56%; P=.4) did not differ.

Negative or uncertain findings: The active control was highly active and received trackers and counseling, narrowing separation. The prescribed program did not show superior primary or clinical outcomes.

Limits and applicability

Single comprehensive-center trial, unblinded, with substantial outcome missingness. Associations between activity and outcomes in pooled analyses are not randomized comparisons.

Funding and conflicts: Funding and conflict details were not fully verified for this record.

Safety context

Pancreatic treatment can cause weight loss, dehydration, biliary infection, neuropathy and thrombosis. Nutrition and symptom monitoring are essential; severe pain, fever, jaundice, dizziness or rapid decline should prompt clinical review.

Questions for the care team

Is weight and protein intake adequate for resistance training?
Which symptoms should pause home exercise?
Would supervised rehabilitation be safer with frailty or neuropathy?

Primary sources

Last literature search: 29 October 2026. Record appraisal: 29 October 2026. This page is educational and does not replace individualized medical advice. Exercise prescriptions should be adapted to diagnosis, treatment, surgical restrictions, blood counts, cardiopulmonary status, neuropathy, fall risk and bone-metastasis location. Symptom or fitness improvement is not proof of tumor response, recurrence prevention or longer survival unless those outcomes were directly tested.